SG10201900631TA - Compounds active towards bromodomains - Google Patents
Compounds active towards bromodomainsInfo
- Publication number
- SG10201900631TA SG10201900631TA SG10201900631TA SG10201900631TA SG10201900631TA SG 10201900631T A SG10201900631T A SG 10201900631TA SG 10201900631T A SG10201900631T A SG 10201900631TA SG 10201900631T A SG10201900631T A SG 10201900631TA SG 10201900631T A SG10201900631T A SG 10201900631TA
- Authority
- SG
- Singapore
- Prior art keywords
- bromodomains
- compounds active
- active towards
- towards
- compounds
- Prior art date
Links
- 102000001805 Bromodomains Human genes 0.000 title 1
- 108050009021 Bromodomains Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1450919 | 2014-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201900631TA true SG10201900631TA (en) | 2019-02-27 |
Family
ID=53765198
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201700776XA SG11201700776XA (en) | 2014-08-01 | 2015-07-29 | Compounds active towards bromodomains |
SG10201900631TA SG10201900631TA (en) | 2014-08-01 | 2015-07-29 | Compounds active towards bromodomains |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201700776XA SG11201700776XA (en) | 2014-08-01 | 2015-07-29 | Compounds active towards bromodomains |
Country Status (19)
Country | Link |
---|---|
US (1) | US10752640B2 (es) |
EP (1) | EP3174868B1 (es) |
JP (1) | JP6759514B2 (es) |
KR (2) | KR102633122B1 (es) |
CN (1) | CN106573915B (es) |
AU (1) | AU2015295405B2 (es) |
BR (1) | BR112017002053A2 (es) |
CA (1) | CA2956871C (es) |
CL (1) | CL2017000240A1 (es) |
CO (1) | CO2017001994A2 (es) |
DK (1) | DK3174868T3 (es) |
ES (1) | ES2896400T3 (es) |
IL (1) | IL250320B (es) |
MA (1) | MA40551A (es) |
MY (1) | MY187540A (es) |
RU (1) | RU2743074C2 (es) |
SG (2) | SG11201700776XA (es) |
WO (1) | WO2016016316A1 (es) |
ZA (1) | ZA201700670B (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2990403A1 (en) | 2014-08-29 | 2016-03-02 | Novartis Tiergesundheit AG | Anthranilamides, sulfonamides and nitro analogues derived therefrom as anthelmintics |
US10696637B2 (en) | 2015-07-17 | 2020-06-30 | Fujifilm Corporation | Nitrogen-containing heterocyclic compound |
MX2018009870A (es) * | 2016-02-15 | 2018-11-29 | Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh | Inhibidores de taf1 para la terapia del cancer. |
CA3018358A1 (en) * | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyridyl derivatives as bromodomain inhibitors |
CN109983001B (zh) | 2016-07-12 | 2023-04-04 | 锐新医药公司 | 作为变构shp2抑制剂的2,5-双取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪 |
US20190247302A1 (en) * | 2016-10-21 | 2019-08-15 | University Of Miami | Materials and methods for treating ophthalmic inflammation |
BR112019013273A2 (pt) | 2016-12-27 | 2019-12-17 | Fujifilm Corp | agente antitumoral e inibidor de bromodomínio |
BR112019014527A2 (pt) | 2017-01-23 | 2020-02-27 | Revolution Medicines, Inc. | Compostos de piridina como inibidores de shp2 alostéricos |
IL296456A (en) | 2017-01-23 | 2022-11-01 | Revolution Medicines Inc | Bicyclics as allosteric shp2 inhibitors |
CA3048278A1 (en) * | 2017-02-07 | 2018-08-16 | Janssen Pharmaceutica Nv | Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis |
WO2019001420A1 (en) | 2017-06-27 | 2019-01-03 | Janssen Pharmaceutica Nv | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING INFECTIONS WITH HEPATITIS B VIRUS |
AU2018347516A1 (en) * | 2017-10-12 | 2020-05-07 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors |
SG11202004090YA (en) | 2017-12-15 | 2020-05-28 | Revolution Medicines Inc | Polycyclic compounds as allosteric shp2 inhibitors |
JP2021512960A (ja) * | 2018-02-06 | 2021-05-20 | シャンハイ ハイファ ファーマシューティカル カンパニー,リミティッド | Bet阻害活性を有する化合物並びにその製造方法及び使用 |
CN110386927B (zh) * | 2018-04-20 | 2022-09-23 | 中国科学院上海药物研究所 | 组蛋白乙酰转移酶(hat)抑制剂及其用途 |
CN109053542A (zh) * | 2018-07-25 | 2018-12-21 | 南通大学 | 一种6-溴-5-羟基异吲哚啉-1-酮的化学合成方法 |
WO2020028461A1 (en) * | 2018-07-31 | 2020-02-06 | The Trustees Of Princeton University | Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers |
US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
CA3117927A1 (en) | 2018-11-02 | 2020-05-07 | Merck Sharp & Dohme Corp. | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors |
WO2021083949A1 (en) * | 2019-10-29 | 2021-05-06 | F. Hoffmann-La Roche Ag | Bifunctional compounds for the treatment of cancer |
GB201918587D0 (en) * | 2019-12-17 | 2020-01-29 | Artios Pharma Ltd | Novel compounds |
IL294705A (en) * | 2020-01-24 | 2022-09-01 | Univ Princeton | Heterocyclic compounds and their uses |
CN116745288A (zh) * | 2020-11-10 | 2023-09-12 | 福霍恩治疗公司 | 化合物及其用途 |
GB202019475D0 (en) | 2020-12-10 | 2021-01-27 | Cancer Research Tech Ltd | Therapeutic compounds and their use |
WO2022159445A1 (en) * | 2021-01-19 | 2022-07-28 | Metrea Biosciences, Inc. | Compounds and methods of activating lipoprotein lipase |
CN117479935A (zh) * | 2021-04-19 | 2024-01-30 | 上海药苑生物科技有限公司 | 用于治疗川崎病的苯并噻唑和喹啉衍生物 |
WO2023274418A1 (zh) * | 2021-07-02 | 2023-01-05 | 南京明德新药研发有限公司 | 蛋白降解靶向嵌合体类化合物 |
KR20240063881A (ko) * | 2021-07-30 | 2024-05-13 | 콘포 테라퓨틱스 엔.브이. | 통증, 특히 신경병증성 통증, 및/또는 at2r 및/또는 at2r 매개 신호전달과 연관된 다른 질환 또는 장애의 치료를 위한 화합물 |
WO2023205251A1 (en) | 2022-04-19 | 2023-10-26 | Nuevolution A/S | Compounds active towards bromodomains |
WO2023205475A1 (en) * | 2022-04-21 | 2023-10-26 | Nimbus Clotho, Inc. | Ctps1 inhibitors and uses thereof |
WO2023248193A1 (en) * | 2022-06-24 | 2023-12-28 | Zydus Lifesciences Limited | Treatment for glomerular diseases |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5328935B2 (es) | 1972-01-20 | 1978-08-17 | ||
JPS56104333A (en) * | 1980-01-23 | 1981-08-20 | Fuji Photo Film Co Ltd | Color photographic sensitive material |
DE3445669A1 (de) | 1984-12-14 | 1986-06-19 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue pyrrolo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
JPS6232459A (ja) | 1985-08-05 | 1987-02-12 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料 |
JPS6238463A (ja) | 1985-08-14 | 1987-02-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−感光材料の画像形成方法 |
JPH067250B2 (ja) | 1985-10-18 | 1994-01-26 | 富士写真フイルム株式会社 | ハロゲン化銀カラ−写真感光材料 |
JPS6292939A (ja) | 1985-10-19 | 1987-04-28 | Fuji Photo Film Co Ltd | 熱現像感光材料 |
JPH0756566B2 (ja) | 1985-11-06 | 1995-06-14 | 富士写真フイルム株式会社 | ハロゲン化銀カラ−写真感光材料の処理方法 |
JPS62129853A (ja) | 1985-11-30 | 1987-06-12 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料 |
JPS62153953A (ja) | 1985-12-27 | 1987-07-08 | Fuji Photo Film Co Ltd | カラ−写真感光材料 |
JPS62173466A (ja) | 1986-01-28 | 1987-07-30 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料 |
JPS62222251A (ja) | 1986-02-17 | 1987-09-30 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料の処理方法 |
JPS62257158A (ja) | 1986-04-30 | 1987-11-09 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料 |
EP0254280B1 (en) | 1986-07-22 | 1993-12-29 | Fuji Photo Film Co., Ltd. | Method for processing silver halide color photographic material |
DE3803775A1 (de) | 1988-02-09 | 1989-08-17 | Boehringer Mannheim Gmbh | Neue substituierte lactame, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten |
JPH02234158A (ja) | 1989-03-07 | 1990-09-17 | Fuji Photo Film Co Ltd | カラー感光材料 |
JPH02264946A (ja) | 1989-04-05 | 1990-10-29 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
JPH02267548A (ja) | 1989-04-10 | 1990-11-01 | Fuji Photo Film Co Ltd | 画像形成法 |
DE3925584A1 (de) | 1989-08-02 | 1991-02-07 | Boehringer Mannheim Gmbh | Neue n-(dimethyloxophosphinylmethyl-)-lactame, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
DE4027592A1 (de) | 1990-08-31 | 1992-03-05 | Beiersdorf Ag | Neue pyrrolobenzimidazole, imidazobenzoxazinone und imidazochinolone, verfahren zu ihrer herstellung und ihre verwendung sowie die verbindungen enthaltende zubereitungen |
JPH04315148A (ja) | 1991-04-15 | 1992-11-06 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
GB9205702D0 (en) | 1992-03-16 | 1992-04-29 | Fujisawa Pharmaceutical Co | A new use of a quinazoline derivative |
DE69310098T2 (de) | 1992-10-15 | 1997-07-31 | Fuji Photo Film Co Ltd | Verarbeitungsverfahren für farbphotographisches Silberhalogenidmaterial |
AU701776B2 (en) | 1994-05-27 | 1999-02-04 | Merck & Co., Inc. | Compounds for inhibiting osteoclast-mediated bone resorption |
US5756502A (en) | 1994-08-08 | 1998-05-26 | Warner-Lambert Company | Quinazolinone derivatives as cholyecystokinin (CCK) ligands |
TW381092B (en) | 1995-07-07 | 2000-02-01 | Otsuka Pharma Co Ltd | Novel benzimidazole derivatives for use in treating arteriosclerotic diseases |
US5747235A (en) | 1996-01-26 | 1998-05-05 | Eastman Kodak Company | Silver halide light sensitive emulsion layer having enhanced photographic sensitivity |
US5780480A (en) | 1996-02-28 | 1998-07-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
JP2000505471A (ja) | 1996-02-28 | 2000-05-09 | メルク エンド カンパニー インコーポレーテッド | フィブリノーゲン受容体拮抗物質 |
JP2002511054A (ja) | 1996-12-30 | 2002-04-09 | メルク エンド カンパニー インコーポレーテッド | ファルネシル蛋白トランスフェラーゼ阻害薬 |
UA71555C2 (en) | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
EP1047691A1 (en) | 1997-12-12 | 2000-11-02 | Smithkline Beecham Plc | Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists |
EP1049664B1 (en) | 1997-12-22 | 2005-03-16 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
DE19839499A1 (de) | 1998-08-29 | 2000-03-02 | Merck Patent Gmbh | 2-Oxo-2H-chinolinderivate |
US6777413B2 (en) | 2000-02-01 | 2004-08-17 | Millennium Pharmaceuticals, Inc. | 2-[1H]-quinolone and 2-[1H]-quinoxalone inhibitors of factor Xa |
JP2002341484A (ja) | 2001-03-12 | 2002-11-27 | Fuji Photo Film Co Ltd | 熱現像感光材料 |
JP2002296731A (ja) | 2001-03-30 | 2002-10-09 | Fuji Photo Film Co Ltd | 熱現像カラー画像記録材料 |
WO2002090347A1 (en) | 2001-04-30 | 2002-11-14 | Fujisawa Pharmaceutical Co., Ltd. | Amide compounds |
BR0209687A (pt) | 2001-05-15 | 2004-09-14 | Du Pont | Método de controle de doenças vegetais, composto e composição |
JP2003321472A (ja) | 2002-02-26 | 2003-11-11 | Takeda Chem Ind Ltd | Grk阻害剤 |
EP1388342A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
EP1539754A4 (en) | 2002-08-23 | 2009-02-25 | Novartis Vaccines & Diagnostic | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF |
US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
US7563807B2 (en) | 2002-09-17 | 2009-07-21 | Merck & Co. Inc. | Removal of aldehyde impurity by reactive polystyrene resini |
EP1572212A2 (en) | 2002-12-11 | 2005-09-14 | 7TM Pharma A/S | Quinoline compounds for use in mch receptor related disorders |
US20040142950A1 (en) | 2003-01-17 | 2004-07-22 | Bunker Amy Mae | Amide and ester matrix metalloproteinase inhibitors |
US7205318B2 (en) | 2003-03-18 | 2007-04-17 | Bristol-Myers Squibb Company | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors |
EP1628666B1 (en) | 2003-05-14 | 2015-09-23 | NeuroGenetic Pharmaceuticals, Inc. | Compouds and uses thereof in modulating amyloid beta |
JP4728962B2 (ja) | 2003-05-19 | 2011-07-20 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 免疫抑制化合物および組成物 |
AU2004288709B2 (en) | 2003-11-07 | 2011-01-06 | Novartis Vaccines And Diagnostics, Inc. | Methods for synthesizing quinolinone compounds |
WO2005087742A1 (en) | 2004-03-08 | 2005-09-22 | Exelixis, Inc. | Metabolic kinase modulators and methods of use as pesticides |
WO2005094805A1 (ja) | 2004-04-01 | 2005-10-13 | Institute Of Medicinal Molecular Design. Inc. | イミン誘導体及びアミド誘導体 |
US7312335B2 (en) | 2004-06-03 | 2007-12-25 | Brandeis University | Asymmetric Michael and Aldol additions using bifunctional cinchona-alkaloid-based catalysts |
GB0416730D0 (en) | 2004-07-27 | 2004-09-01 | Novartis Ag | Organic compounds |
EP1655295A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
UY29198A1 (es) | 2004-11-09 | 2006-05-31 | Cancer Rec Tech Ltd | Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones |
WO2006105222A2 (en) | 2005-03-25 | 2006-10-05 | Scios Inc. | Carboxamide inhibitors of tgfb |
GB0509227D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
GB0509224D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of intracellular enzymatic activity |
WO2006130437A2 (en) | 2005-05-27 | 2006-12-07 | Brandeis University | Asymmetric carbon-carbon-bond-forming reactions catalyzed by bifunctional cinchona alkaloids |
KR20080048551A (ko) | 2005-09-23 | 2008-06-02 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 1H-이미다조[4,5-c]피리딘 및 그의 유사체의 제조법 |
AU2007214661B2 (en) | 2006-02-16 | 2012-05-17 | Syngenta Limited | Pesticides containing a bicyclic bisamide structure |
GB0605689D0 (en) | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
EP2023926B1 (en) | 2006-05-19 | 2011-10-12 | Bayer Pharma Aktiengesellschaft | Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders |
WO2008029152A2 (en) | 2006-09-08 | 2008-03-13 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
CA2665438C (en) | 2006-10-04 | 2014-12-02 | Tibotec Pharmaceuticals Ltd. | Carboxamide 4-[(4-pyridyl)amino]pyrimidines useful as hcv inhibitors |
US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
AU2008219166B2 (en) | 2007-02-16 | 2013-05-16 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors |
US20080221093A1 (en) * | 2007-03-07 | 2008-09-11 | Christian Gege | Metalloprotease inhibitors containing a heterocyclic moiety |
US8039505B2 (en) | 2007-04-11 | 2011-10-18 | University Of Utah Research Foundation | Compounds for modulating T-cells |
JP2008280341A (ja) | 2007-04-12 | 2008-11-20 | Sumitomo Chemical Co Ltd | ヒドラジド化合物およびその防除用途 |
WO2009020677A2 (en) | 2007-04-27 | 2009-02-12 | University Of Rochester | Compositions and methods for inhibiting g protein signaling |
EP2008658A1 (en) | 2007-06-28 | 2008-12-31 | Bayer Schering Pharma Aktiengesellschaft | Synergistic combination of anthranilamide pyridinureas and benzamide derivatives |
CN102746239B (zh) | 2007-09-17 | 2016-02-10 | 艾伯维巴哈马有限公司 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
CN102089278A (zh) | 2008-06-11 | 2011-06-08 | Irm责任有限公司 | 用于治疗疟疾的化合物和组合物 |
US20100068204A1 (en) | 2008-09-12 | 2010-03-18 | Wyeth | 4-aryloxyquinolin-2(1h)-ones as mtor kinase and pi3 kinase inhibitors, for use as anti-cancer agents |
WO2010045374A1 (en) | 2008-10-15 | 2010-04-22 | Gilead Palo Alto, Inc. | 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors |
KR101381074B1 (ko) | 2008-12-23 | 2014-04-11 | 에프. 호프만-라 로슈 아게 | P2x7 조절제로서의 디히드로피리돈 아미드 |
MX2011009213A (es) | 2009-03-02 | 2011-12-14 | Sirtris Pharmaceuticals Inc | Quinolinas 8-sustituidas y analogos relacionados como moduladores de sirtuina. |
US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
US8362249B2 (en) | 2009-04-27 | 2013-01-29 | Boehringer Ingelheim International Gmbh | CXCR3 receptor antagonists |
UA107360C2 (en) | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
ES2563057T3 (es) * | 2009-11-05 | 2016-03-10 | Glaxosmithkline Llc | Inhibidor de bromodominio de benzodiazepina |
AU2011245441B2 (en) | 2010-04-29 | 2014-12-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Activators of human pyruvate kinase |
EP2571878B1 (en) | 2010-05-17 | 2018-10-17 | Incozen Therapeutics Pvt. Ltd. | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases |
WO2011156632A2 (en) | 2010-06-09 | 2011-12-15 | Georgetown University | Compositions and methods of treatment for tumors in the nervous system |
WO2012020820A1 (ja) | 2010-08-11 | 2012-02-16 | 大正製薬株式会社 | ヘテロアリール-ピラゾール誘導体 |
AR084070A1 (es) * | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
WO2012080284A2 (en) | 2010-12-17 | 2012-06-21 | F. Hoffmann-La Roche Ag | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof |
TW201309639A (zh) | 2011-02-17 | 2013-03-01 | Lg Life Sciences Ltd | 作為gpr119促效劑之肟衍生物 |
WO2012125668A1 (en) | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
GB201106743D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
GB201106750D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
JP5742439B2 (ja) | 2011-05-02 | 2015-07-01 | 信越化学工業株式会社 | 蛍光性化合物及び蛍光性樹脂組成物 |
US9278910B2 (en) | 2011-05-31 | 2016-03-08 | Receptos, Inc. | GLP-1 receptor stabilizers and modulators |
CN102887895B (zh) | 2011-07-22 | 2016-08-24 | 山东轩竹医药科技有限公司 | 吡啶并嘧啶类mTOR抑制剂 |
WO2013019682A1 (en) | 2011-07-29 | 2013-02-07 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
WO2013027168A1 (en) * | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
EP2766345B1 (en) * | 2011-10-14 | 2016-03-16 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
WO2013063462A2 (en) | 2011-10-26 | 2013-05-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of treating hcv infection with a small molecule chk2 inhibitor |
KR102067235B1 (ko) | 2012-04-25 | 2020-01-16 | 라퀄리아 파마 인코포레이티드 | Ttx-s 차단제로서 아미드 유도체 |
JPWO2014034719A1 (ja) | 2012-08-29 | 2016-08-08 | 興和株式会社 | Tlr阻害作用を有するキノリン誘導体 |
WO2014095774A1 (de) | 2012-12-20 | 2014-06-26 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische dihydropyridopyrazinone |
EP2935261A1 (de) | 2012-12-20 | 2015-10-28 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische dihydrochinoxalinone |
-
2015
- 2015-07-29 EP EP15744908.3A patent/EP3174868B1/en active Active
- 2015-07-29 CN CN201580041641.4A patent/CN106573915B/zh active Active
- 2015-07-29 SG SG11201700776XA patent/SG11201700776XA/en unknown
- 2015-07-29 KR KR1020237030114A patent/KR102633122B1/ko active IP Right Grant
- 2015-07-29 CA CA2956871A patent/CA2956871C/en active Active
- 2015-07-29 MY MYPI2017000169A patent/MY187540A/en unknown
- 2015-07-29 SG SG10201900631TA patent/SG10201900631TA/en unknown
- 2015-07-29 US US15/501,058 patent/US10752640B2/en active Active
- 2015-07-29 MA MA040551A patent/MA40551A/fr unknown
- 2015-07-29 WO PCT/EP2015/067400 patent/WO2016016316A1/en active Application Filing
- 2015-07-29 BR BR112017002053-0A patent/BR112017002053A2/pt active Search and Examination
- 2015-07-29 DK DK15744908.3T patent/DK3174868T3/da active
- 2015-07-29 ES ES15744908T patent/ES2896400T3/es active Active
- 2015-07-29 KR KR1020177005648A patent/KR20170038877A/ko not_active IP Right Cessation
- 2015-07-29 RU RU2017104510A patent/RU2743074C2/ru not_active Application Discontinuation
- 2015-07-29 AU AU2015295405A patent/AU2015295405B2/en active Active
- 2015-07-29 JP JP2017505176A patent/JP6759514B2/ja active Active
-
2017
- 2017-01-26 IL IL250320A patent/IL250320B/en unknown
- 2017-01-26 ZA ZA2017/00670A patent/ZA201700670B/en unknown
- 2017-01-30 CL CL2017000240A patent/CL2017000240A1/es unknown
- 2017-02-28 CO CONC2017/0001994A patent/CO2017001994A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20170038877A (ko) | 2017-04-07 |
US20170349607A1 (en) | 2017-12-07 |
WO2016016316A1 (en) | 2016-02-04 |
IL250320B (en) | 2022-02-01 |
ZA201700670B (en) | 2020-07-29 |
KR20230133395A (ko) | 2023-09-19 |
AU2015295405A1 (en) | 2017-03-09 |
CA2956871A1 (en) | 2016-02-04 |
ES2896400T3 (es) | 2022-02-24 |
MA40551A (fr) | 2021-04-07 |
RU2017104510A3 (es) | 2019-02-11 |
CN106573915A (zh) | 2017-04-19 |
DK3174868T3 (da) | 2021-11-08 |
SG11201700776XA (en) | 2017-02-27 |
EP3174868B1 (en) | 2021-08-25 |
IL250320A0 (en) | 2017-03-30 |
RU2017104510A (ru) | 2018-09-03 |
CA2956871C (en) | 2021-05-18 |
US10752640B2 (en) | 2020-08-25 |
MY187540A (en) | 2021-09-28 |
JP6759514B2 (ja) | 2020-09-23 |
RU2743074C2 (ru) | 2021-02-15 |
CO2017001994A2 (es) | 2017-05-19 |
CL2017000240A1 (es) | 2017-10-06 |
AU2015295405B2 (en) | 2020-04-09 |
EP3174868A1 (en) | 2017-06-07 |
CN106573915B (zh) | 2020-12-25 |
NZ729136A (en) | 2021-01-29 |
JP2017522346A (ja) | 2017-08-10 |
KR102633122B1 (ko) | 2024-02-05 |
BR112017002053A2 (pt) | 2018-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201700670B (en) | Compounds active towards bromodomains | |
AP2017009836A0 (en) | Aminopyridyloxypyrazole compounds | |
GB201415573D0 (en) | Compounds | |
GB201411418D0 (en) | Compounds | |
GB201418300D0 (en) | Compounds | |
GB201410430D0 (en) | Compounds | |
GB201402431D0 (en) | Compounds | |
GB201417369D0 (en) | Compounds | |
GB2540892B (en) | Pyrrolobenzodiazepine compounds | |
GB201416186D0 (en) | Compounds | |
GB201404987D0 (en) | Compounds | |
GB201417561D0 (en) | Compounds | |
GB201406591D0 (en) | Compounds | |
GB201419228D0 (en) | Compounds | |
GB201406956D0 (en) | Compounds | |
SG11201701225YA (en) | Azetidinyloxyphenylpyrrolidine compounds | |
GB201419264D0 (en) | Compounds | |
GB201412660D0 (en) | Compounds | |
GB201417168D0 (en) | Compounds | |
GB201419015D0 (en) | Compounds | |
GB201407695D0 (en) | Compounds | |
GB201405361D0 (en) | Compounds | |
AU2014324V (en) | MALOF002 Acmena smithii | |
GB201419722D0 (en) | Compounds | |
GB201419321D0 (en) | Compounds |